department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Armata Pharmaceuticals, Inc. ($ARMP) · pharmadog

PUBLIC COMPANY

$ARMPArmata Pharmaceuticals, Inc.

Los Angeles, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 2

Resistant Pseudomonas aeruginosa Infections

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Armata Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$ARMP

SEC CIK

0000921114

country

US

source

sec_tickers

top tags

Infectious Disease2 Cystic Fibrosis1 Pulmonology1

mentioned in

0news items

entity-linker matched

$ARMP

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremiacompletedn=56
phase2Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infectioncompletedn=48
phase2Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosiscompletedn=29

Data sources

last refreshed 3m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Mar 14, 26tax coverBirx Deborah · Chief Executive Officer4,919 sh
Mar 14, 26tax coverKyme Pierre · Chief Business Officer1,030 sh
Mar 9, 26grantKyme Pierre · Chief Business Officer183,142 sh
Mar 9, 26grantHouse David Duane · SVP, Finance, and PFO109,885 sh
Mar 9, 26grantPATTI JOSEPH M · 25,640 sh
Mar 9, 26grantPeterson Todd C. · 25,640 sh